Exdensur (depemokimab) has been approved by Health Canada for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). This long-acting biologic is the first of its kind to offer twice-yearly dosing for these conditions, which are often difficult to manage. The approval is based on data from the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen for depemokimab versus placebo.
Severe asthma, characterized by an eosinophilic phenotype, affects approximately half of those living with asthma in Canada, leading to over 80,000 emergency room visits annually. CRSwNP, on the other hand, is estimated to affect hundreds of thousands of Canadians, causing symptoms such as nasal obstruction, loss of smell, facial pain, sleep disturbance, infections, and nasal discharge. These conditions significantly impact the emotional and physical well-being of those affected.
Depemokimab targets human interleukin-5 (IL-5), a key cytokine involved in eosinophilic inflammation, which is a common driver in difficult-to-treat asthma and up to 85% of CRSwNP cases. The drug's extended half-life, high-binding affinity, and specificity enable its twice-yearly dosing regimen, making it a valuable addition to the treatment landscape for these conditions.
The SWIFT and ANCHOR trials showed that Exdensur reduced asthma exacerbations, including those requiring hospitalization and emergency department visits, and improved nasal polyp size and obstruction for CRSwNP patients. The drug was well-tolerated, with patients experiencing similar rates and severities of side effects as those receiving placebo.
This approval is a significant milestone for Canadian patients, offering a differentiated treatment option with the potential to improve disease management and patient outcomes. However, it is important to advocate for timely and equitable access to ensure that this promising therapy can genuinely help those who need it.
